Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tonu Vanakesa"'
Autor:
Tonu Vanakesa, Oleg Gladkov, Katalin Udud, Patrick Therasse, Byoung Chul Cho, Jean-Louis Pujol, Moon Soo Kim, Libor Havel, Johan Vansteenkiste, Hans Hoffman, Nasser K. Altorki, Haruhiko Kondo, Paul D. Taylor, Jacek Jassem, Marcin Zieliński, Mei Lin Liao, Jamila Louahed, Tetsuya Mitsudomi, Tommaso De Pas, Konstantinos Zarogoulidis, Anders Bugge, Jubrail Dahabreh, Vincent Brichard, Muriel Debois, Haruhiku Nakayama, Jianxing He, Hirohito Tada, Masahiro Yoshimura, Emilio Esteban Gonzalez, C. Debruyne
Publikováno v:
The Lancet Oncology. 17:822-835
Summary Background Fewer than half of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no substantial progress has been made in adjuvant treatment. We aimed t
Autor:
Jakub Perdeus, Jacek Jassem, Frederic Lehmann, A Linder, Emilio Esteban Gonzalez, Reiner Bonnet, Jubrail Dahabreh, Richard Janilionis, Haralabos P. Kalofonos, Marc Gillet, Johan Vansteenkiste, Vincent Brichard, W. Malinowski, Marta López-Brea, Jazeps Basko, Tom Treasure, Tonu Vanakesa, Bernward Passlick, Marcin Zieliński
Publikováno v:
Journal of Clinical Oncology. 31:2396-2403
Purpose The MAGE-A3 protein is expressed in approximately 35% of patients with resectable non–small-cell lung cancer (NSCLC). Several immunization approaches against the MAGE-A3 antigen have shown few, but often long-lasting, clinical responses in
Autor:
Vincent Brichard, Byoung Chul Cho, M.S. Kim, Masahiro Yoshimura, Johan Vansteenkiste, Nasser K. Altorki, Jacek Jassem, Marcin Zieliński, P. Therasse, Tetsuya Mitsudomi, C. Debruyne, Konstantinos Zarogoulidis, B. Spiessens, Haruhiko Kondo, Jubrail Dahabreh, Tonu Vanakesa, Haruhiko Nakayama, T. De Pas, Libor Havel, Oleg Gladkov
Publikováno v:
Annals of Oncology. 25:iv409
Aim: Adjuvant chemotherapy (ACT) is the standard of care for Stage II and IIIA NSCLC, and for high risk Stage IB NSCLC. However, the 5-year disease-free survival remains poor (35-50%) and about half of the patients will not receive ACT for various re
Autor:
A Linder, Emilio Esteban, Jacek Jassem, J. Dahabre, Marcin Zieliński, W. Malinowski, Johan Vansteenkiste, Marta López-Brea, Tonu Vanakesa, Bernward Passlick
Publikováno v:
European Journal of Cancer Supplements. 5:361